Alopecia

Posts

Global Alopecia Treatment Market

Speaker discusses use of JAK inhibitors in alopecia

Speaker discusses use of JAK inhibitors in alopecia

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

Antonella Tosti, MD, said that JAK inhibitors “are probably the future of treatment for alopecia areata.”

Of the three main JAK inhibitors used for alopecia areata — ruxolitinib, baricitinib and tofacitinib — tofacitinib “has been most studied,” Tosti said. The standard dose of tofacitinib is 5 mg twice daily.

Patients usually regrow hair about 3 months after beginning treatment, and even though some patients may take longer, they should “persist and continue the treatment,” she said.

About 70% of patients respond to tofacitinib, although it is typically less effective in long-standing alopecia totalis or alopecia universalis. However, the oral formulation is more effective than the topical formulation, Tosti said.

Large clinical trials for ruxolitinib and baricitinib are ongoing, according to Tosti. In the literature cited during the presentation, ruxolitinib doses were 10 mg twice daily and 10 mg every other day. She also said “usually ruxolitinib causes visible regrowth earlier than tofacitinib.”

There is not yet data on long-term side effects, but patients commonly experience upper respiratory infections, headache and weight gain. Given the potential danger of upper respiratory infections during the era of COVID-19, Tosti has advised her patients to discontinue treatment if they develop COVID-19 symptoms. Other side effects, such as severe infection, have been reported among patients taking a JAK inhibitor for another indication.

Tosti said there are several JAK inhibitor compounds in the phase 2 or 3 stage of development.

Speaker discusses use of JAK inhibitors in alopecia

Source

Recent Posts

Global Alopecia Treatment Market

Speaker discusses use of JAK inhibitors in alopecia

Speaker discusses use of JAK inhibitors in alopecia

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

Antonella Tosti, MD, said that JAK inhibitors “are probably the future of treatment for alopecia areata.”

Of the three main JAK inhibitors used for alopecia areata — ruxolitinib, baricitinib and tofacitinib — tofacitinib “has been most studied,” Tosti said. The standard dose of tofacitinib is 5 mg twice daily.

Patients usually regrow hair about 3 months after beginning treatment, and even though some patients may take longer, they should “persist and continue the treatment,” she said.

About 70% of patients respond to tofacitinib, although it is typically less effective in long-standing alopecia totalis or alopecia universalis. However, the oral formulation is more effective than the topical formulation, Tosti said.

Large clinical trials for ruxolitinib and baricitinib are ongoing, according to Tosti. In the literature cited during the presentation, ruxolitinib doses were 10 mg twice daily and 10 mg every other day. She also said “usually ruxolitinib causes visible regrowth earlier than tofacitinib.”

There is not yet data on long-term side effects, but patients commonly experience upper respiratory infections, headache and weight gain. Given the potential danger of upper respiratory infections during the era of COVID-19, Tosti has advised her patients to discontinue treatment if they develop COVID-19 symptoms. Other side effects, such as severe infection, have been reported among patients taking a JAK inhibitor for another indication.

Tosti said there are several JAK inhibitor compounds in the phase 2 or 3 stage of development.

Speaker discusses use of JAK inhibitors in alopecia

Source

Recent Posts

Global Alopecia Treatment Market

Study Results for the Treatment of Androgenic Alopecia

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Histogen today announced week 26 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 26 timepoint, patients treated with HST-001 demonstrated a statistically significant change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system.

HST-001 was also shown to be safe and well-tolerated at week 26 as compared to placebo with no reports of serious adverse events. Similar to the week 18 primary endpoint results we reported in December of 2020, HST-001 did not achieve statistical significance at week 26 when compared to placebo.

“The recently completed study demonstrated that HST-001 was safe, well-tolerated, and exhibited signals of efficacy. This data will inform future development, and I look forward to working with Histogen and our other expert advisors as we plan and execute the next study in men with androgenetic alopecia,” said Dr Stacy Smith, M.D., founder of the California Dermatology and Clinical Research Institution and principal investigator for the HST-001 trial.

“We are encouraged that these results demonstrated that patients treated with HST-001 grow both terminal and vellus hairs in men with androgenic alopecia,” said Richard W. Pascoe, Histogen’s President and CEO. “Moreover, 84% of the subjects who received HST-001 responded to treatment over the 26-week period and the study drug was found to be safe and well-tolerated across all subjects.

With this data in hand, we have begun planning for a more substantive clinical trial in men with androgenic alopecia with the goal of determining the best clinical pathway for future registration trials. We anticipate the trial will commence in the second half of 2021.”

About the HST-001 Phase 1a/2b Study
This 2:1 randomized, blinded, the placebo-controlled, single-site study enrolled 36 male patients with androgenic alopecia with mild to moderate hair loss on a Norwood-Hamilton (N-H) Scale (3V, 4, 5), with a total of 30 evaluable patients at week 26.

It was designed to assess the safety and tolerability of HST-001, as well as indicators of efficacy at weeks 18 and 26. The primary study endpoint is an absolute change from baseline versus week 18 in total hairs (terminal and vellus) in the (TAHC) of the vertex as measured by Canfield’s Hairmetrix macrophotography system.

Secondary endpoints include absolute change from baseline in total hairs (terminal and vellus) new terminal and vellus hair count, hair thickness density and per cent change from baseline in TAHC, terminal and vellus hair counts in the vertex and right temporal regions at weeks 18 and 26, all as measured by Canfield’s Hairmetrix macrophotography system. At each treatment time point (Weeks 0, 6 and 12), patients received a total of 20 injections, 10 in the vertex scalp region and 5 in each temporal region for a total dose of 2mL.

About HST-001
HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signaling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function.

Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

For more information, please visit www.histogen.com.

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Source

Recent Posts

Preclinical Study of Hair Loss Therapeutic Candidate

Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals, Inc, a leading developer of RNAi therapeutics, announced that it has demonstrated efficacy in a preclinical study of OLX104C, an investigational RNAi therapeutic in development for androgenic alopecia, also known as hair loss.

In the study, OLX104C was administered topically to a mouse model with suppressed hair growth (Dihydrotestosterone, DHT administered mouse). The study evaluated the percentage of hair regrowth and duration of knockdown of the target protein, AR, following a single injection.

Mice receiving OLX104C showed substantial hair regrowth compared to the control group, and results showed that a single dose could inhibit the expression of the target gene for more than three weeks.

“We are advancing a novel and potentially durable approach to treating hair loss with large market potential,” said Dong Ki Lee, PhD, founder and chief executive officer of OliX Pharmaceuticals. “Due to topical administration, our investigational therapy acts directly on the affected area and is rapidly degraded upon exposure to the blood, so it’s free from major systemic side effects such as sexual dysfunction caused by conventional hair loss therapeutics.

Building on our experience evaluating RNAi therapeutics for skin diseases, we plan to initiate clinical trials of OLX104C by 2022.”

According to Inkwood Research, the global hair loss treatment market size is estimated to grow 5.51% annually from $8.4 billion in 2018 to $13.6 billion in 2027.1

Furthermore, OliX has completed patent applications in major global markets, including the United States, Europe, Korea, and Japan, to secure exclusive rights for its hair loss treatment substance.

Dr Lee will discuss the preclinical results of OLX104C and present a corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11, 2021, at 9:40 a.m. GMT.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology.

Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain.

OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

To learn more about the company, visit https://www.olixpharma.com/eng/

1 Inkwood Research. Global Alopecia (Hair Loss) Treatment Market Forecast 2019-2027. Available at: https://www.inkwoodresearch.com/reports/global-alopecia-hair-loss-treatment-market/. Accessed February 9, 2021.

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment

Market Research Report 2021-2027

The Global Alopecia Treatment Market poised to grow from US$ XX million in 2021 to US$ XX million by 2027 at a compound annual growth rate (CAGR) of XX% during the projection period of 2021-2027.

The report states that the Alopecia Treatment market condition and market forces acting across the industry. Analysts use the most recent primary and secondary research techniques and tools to arrange comprehensive and accurate marketing research reports. The research study also includes other types of analysis such as qualitative and quantitative.

All proportion of shares and breakdowns are determined using secondary sources and verified primary sources. The report could be a collection of first-hand info, qualitative and quantitative assessment by industry analysts, and industry participants across the value chain.

COVID-19 Impact Evaluation

This report also analyses the impact of Coronavirus COVID-19 on the Xxx industry.

Based on our recent survey, we have several different scenarios about the Xxx YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Xxx will reach xx in 2026, with a CAGR of xx% from 2021 to 2027.

Market Dynamics:

The research report provides analysis and information according to market segments such as geographies, product type, application, and end-use industry. Featuring worldwide and over leading key player profiles, this report serves the ultimate guide to exploring opportunities in the Alopecia Treatment industry globally.

The Alopecia Treatment market report provides effective guidelines and strategies for industry players to secure a position at the top in the worldwide Alopecia Treatment market. Our experts have added large key companies who play an important role in the sales, and distribution of the products. The significant applications and potential business arenas are also added to this report. It encourages the client to make strategic moves and create their businesses.

Moreover, the Alopecia Treatment market report includes information on major product categories, their demand, supply, developments, recent product approvals regulatory scenario and competitive intelligence. The regional scope of the report covers major geographical market places; North America, Europe, Asia-Pacific, Latin America and the Middle East along with market numbers, and growth potential in form of forecast market values in US$ million. Furthermore, the report also sheds light on the competitive landscape in the industry, talking about the key industry participants, their products and services, strategies, financial information and their positions in the market.

The Alopecia Treatment market report covers the following key industry participants:

Teva Pharmaceutical Industries
Merck
Johnson&Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

The Alopecia Treatment Market is divided into product, application and regional market.

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of the product in terms of US$ value is represented in numerical and graphical format for all the major regional markets.

The Alopecia Treatment market report is segmented into Type by the following categories;

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

The Alopecia Treatment market report is segmented into Application by following categories;

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

Above information is further split with respect to following geographies;

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Asia Pacific
China
Japan
India
South Korea
Australia
Middle East and Africa
Saudi Arabia
UAE
South Africa
South America
Brazil
Argentina

Key Information and data offered by the Alopecia Treatment market report:

Market definition, scope and assumptions

Market drivers, restraints, opportunity and challenges

Product market value and future projections in US$ million

Tabular and graphical representation of numbers and growth trend

Alopecia Treatment market estimated in terms of the market size in US$ million and forecast for product, application and regional market

The growth potential and forecast information for Global Alopecia Treatment Market and for segments, by region and by country.

The report includes competitive analysis of the Alopecia Treatment market comprising of key industry players profile. The company profiles offer company overview, business summary, product information, recent development and strategic outlook.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Market Analysis and Insights of Global Alopecia Treatment (Hair Loss) Market

Alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the alopecia treatment (hair loss) market to account to USD 5,461.35 million by 2028 growing at a CAGR of 6.0% in the above-mentioned forecast period.

Rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) has been directly impacting the growth of alopecia treatment (hair loss) market.

Alopecia is a condition that causes hair to fall out in small patches, which can be unnoticeable. These patches may connect, however, and then become noticeable. The condition develops when the immune system attacks the hair follicles, resulting in hair loss.

The increasing need for an effective treatment for alopecia (hair loss) is the main driving factor for the alopecia treatment (hair loss) market. Rising pharmaceutical industries and various research & clinical studies are driving the alopecia treatment (hair loss) market. Various innovative clinical programmes is an opportunity for the alopecia treatment (hair loss) market.

Lack of awareness in rural countries is a big challenge for the alopecia treatment (hair loss) market. However, the high cost of treatment is the main restraint in the growth of alopecia treatment (hair loss) market during the forecast period of 2021-2028.

This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to improve the sales of its product which is Rogaine, a hair loss treatment including minoxidil. JW Pharmaceutical has signed a distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This lead enabled the company to gain more product sales which have increased the company’s overall revenue.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

Alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with a valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on disease type, the alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, cicatricial alopecia, traction alopecia and others.
  • Based on treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment.
  • Based on gender, the alopecia treatment (hair loss) market is segmented into male and female.
  • Based on form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral.
  • Based on end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres.
  • Based distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies.

Alopecia Treatment (Hair Loss) Market Country Level Analysis

Alopecia treatment (hair loss) market is segmented into is analysed and market size insights and trends are provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market is segmented into the report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is likely to lead the alopecia treatment (hair loss) market. The regional market has been driven by a common form of alopecia and people with alopecia aerate affects. However, the growing market with new players is the main factor propelling the growth of the regional market. The market in Asia-Pacific is expected to exhibit a substantial growth rate during the forecast period 2021-2028 due to the rise in prevalence of alopecia and rising usage of hair care therapies for the treatment.

The country section of the alopecia treatment (hair loss) market is segmented into report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import-export analysis, price trend analysis, cost of raw materials, downstream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for alopecia treatment (hair loss) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to alopecia treatment (hair loss) market.

The major players covered in the alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Par Pharmaceutical, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Aurobindo Pharma, Perrigo Company plc, Viviscal Limited, Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech are among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Androgenetic Alopecia Treatment Market

Androgenetic Alopecia Treatment Market Analysis

Androgenetic alopecia (AGA) is a patterned hair loss occurring due to systemic androgen and genetic factors. It is the most common cause of hair loss in both genders. It is characterized by follicular miniaturization in a patterned hair loss occurring due to systemic androgen and genetic factors. The increasing incidence of androgenetic alopecia is expected to boost the market growth.

According to the National Center for Biotechnology Information (NCBI), in August 2015, the global prevalence of severe androgenetic alopecia (AGA) was 15.33% overall and varied significantly by geographical region. The risk of having severe androgenetic alopecia (AGA) increased by 1.092 for per year for the 30 and 40 age group.

The global androgenetic alopecia treatment market is estimated to be valued at US$ 1,607.47 million in 2020 and is expected to exhibit a CAGR of 5.2% during the forecast period (2020-2027).

Product development and ongoing clinical trials are expected to propel the growth of the global androgenetic alopecia treatment market.

Development of drugs for androgenetic alopecia treatment is expecting to boost the market growth over the forecast period. For instance, Cairo University is conducting a clinical trial of topical Cetirizine for the treatment of androgenetic alopecia in females.

The trial is in Phase II/III evaluating the efficacy and tolerability of topical cetirizine in female patients with androgenetic alopecia (AGA). This interventional trial started in February 2020 and the study expected completed in December 2021.

However, side effects of androgenetic alopecia treatment are expected to hinder the market growth. According to the US Pharmacist, a clinically-focused pharmacy publication, published an article- Treatment Options for Androgenetic Alopecia, in 2018 that medication used in for the treatment of androgenetic alopecia has many side effects. For example, topical Minoxidil can cause local erythema and pruritus and Finasteride can cause dizziness, orthostatic hypotension and others.

Report Coverage Details

Base Year:
2019

Market Size in 2020:
US$ 1,607.47 Mn

Historical Data for:
2016 to 2019

Forecast Period:
2020 to 2027

Forecast Period 2020 to 2027 CAGR:
5.3%

2027 Value Projection:
US$ 2,298.34 Mn

Geographies covered:

  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa

Segments covered:

  • By Drug Type: Topical Agents, 5 AR Inhibitors, Others.
  • By Route of Administration: Oral, Topical.
  • By Gender: Male, Female.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.

Companies covered:

Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr. Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd.

Growth Drivers:

  • Rising incidence of androgenetic alopecia
  • Product development and ongoing trials for treatment of androgenetic alopecia

Restraints & Challenges:

  • Side effects of androgenetic alopecia treatment
  • Alternative treatment for androgenetic alopecia treatment

Research and development of treatment for androgenetic alopecia in North America is expected to boost the market growth.

North America is expected to hold dominant position in the global androgenetic alopecia treatment market owing to research and development of treatments for androgenetic alopecia in the region. For instance, on June 4, 2020, Follica, Inc., a biotechnology company developing a regenerative platform designed to treat androgenetic alopecia, and other related conditions, announced positive feedback from the U.S. Food and Drug Administration (FDA) for its FOL-004 Phase II released in December 2019. The company advanced its lead program, FOL-004 into Phase III development, following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia.

Global Androgenetic Alopecia Treatment Market – Impact of Coronavirus (COVID-19) Pandemic

Nationwide lockdowns resulting from COVID-19 in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.

The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.

As a result, the impact of the COVID-19 pandemic is also expected to limit the growth of the global androgenetic alopecia treatment drugs market during the forecast period.

Key Players

Major players operating in the global androgenetic alopecia treatment market are Histogen Inc., Cipla Limited, Aclaris Therapeutics, Inc., Merck & Co., Inc., Daiichi-Sankyo Co., Ltd., Johnson and Johnson Services, Inc., Lexington International LLC, Vita-Cos-Med Klett-Loch GmbH, PureTech, Vitabiotics, Dr Reddy’s Laboratories, HCell Inc., Follica, Inc. and Ranbaxy Laboratories Ltd. among others.

Androgenetic Alopecia Treatment Market Analysis

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Market Analysis and Insights: Global Alopecia Treatment (Hair Loss) Market

The alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2020 to 2027 and is expected to reach USD 5,461.35 million by 2027. The rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) are the major drivers which propelled the demand of the alopecia treatment (hair loss) market in the forecast period.

Alopecia treatment comprises features such as increasing need for an effective treatment for alopecia (hair loss) which will impact in launching new products by the manufacturers into the alopecia treatment (hair loss) market which enhance its demand as well as rising pharmaceutical industries initiatives leads to the alopecia treatment (hair loss) market growth.

Currently, various research & clinical studies are going on which is expected to create a competitive advantage for manufacturers to develop new and innovative alopecia treatment (hair loss) market. Moreover, these clinical programmes are also expected to provide various other opportunities in the alopecia treatment (hair loss) market. However, lack of awareness in rural countries and high cost of treatment is expected to restraint the alopecia treatment (hair loss) market growth in the forecast period.

The alopecia treatment (hair loss) market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the alopecia treatment (hair loss) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

The alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of disease type, the alopecia treatment (hair loss) market is segmented into non-cicatricial alopecia, cicatricial alopecia, traction alopecia and others. In 2020, the non‒cicatricial alopecia segment is dominating the alopecia treatment (hair loss) market as non‒cicatricial alopecia has the highest prevalence rate across the globe and affects a majority of the population.
  • On the basis of treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment. In 2020, localized therapies segment is dominating the alopecia treatment (hair loss) market due to first-line treatment to reduce the symptoms of alopecia and increase the hair growth.
  • On the basis of gender, the alopecia treatment (hair loss) market is segmented into male and female. In 2020, the male segment is dominating the alopecia treatment (hair loss) market due to the large number of male population affected by the androgenetic alopecia.
  • On the basis of form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral. In 2020, the topical segment is dominating the alopecia treatment (hair loss) market as a topical form offers patients with huge compliance and high satisfaction.
  • On the basis of end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres. In 2020, dermatology centres segment is dominating the alopecia treatment (hair loss) market because alopecia is a dermatology related disorder and required innovative treatment solutions for hair loss.
  • On the basis of the distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies. In 2020, pharmacies segment is dominating the alopecia treatment (hair loss) market because, for the treatment of alopecia or hair loss, majority of the formulation are available on OTC, which do not require a prescription and also offers patients with instant gratification.

Global Alopecia Treatment (Hair Loss) Market Country Level Analysis

Global alopecia treatment (hair loss) market is analyzed and market size information is provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and rest of the Middle East and Africa.

Non‒cicatricial alopecia segment in North America region is expected to grow with the highest growth rate in the forecast period of 2020 to 2027 since it is the most common form of alopecia and people with alopecia aerate affects approximately 6.8 million people in the U.S. Japan is leading the growth of the Asia-Pacific alopecia treatment (hair loss) market and non‒cicatricial alopecia segment is dominating in the region due to rise in prevalence of alopecia and rising usage of hair care therapies for the treatment. The non‒cicatricial alopecia segment in Germany is dominating the European alopecia treatment (hair loss) market owing to the increasing demand for effective treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.

Continuous Increasing Awareness for Alopecia Treatment (Hair Loss) is boosting the Alopecia Treatment (Hair Loss) Market Growth

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in alopecia treatment (hair loss) industry with alopecia treatment (hair loss) drugs sales, the impact of advancement in the alopecia treatment (hair loss) technology and changes in regulatory scenarios with their support for the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2018.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to alopecia treatment (hair loss) market.

The major companies which are dealing in the global alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc. (a subsidiary of Teva Pharmaceuticals Industries Ltd.), Pfizer Inc., Par Pharmaceutical (a subsidiary of Endo International plc), GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila), Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp. (a subsidiary of Merck & Co., Inc.), Aurobindo Pharma, Perrigo Company plc, Viviscal Limited (a subsidiary of Church & Dwight Co., Inc.), Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launches and agreements are also initiated by the companies’ worldwide which are also accelerating the alopecia treatment (hair loss) market.

For instance,

  • In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to enhance the sales of its product which is Rogaine, a hair loss treatment containing minoxidil. JW Pharmaceutical has signed an exclusive distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This initiative allowed the company to earn more product sales which has boosted the company’s overall revenue.

Collaboration, product launch, business expansion, award and recognition, joint ventures and other strategies by the market player is enhancing the company market in the alopecia treatment (hair loss) market which also provides the benefit for the organization to improve their offering for alopecia treatment (hair loss).

Customization Available: Global Alopecia Treatment (Hair Loss) Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Global Alopecia Treatment Market – Industry Trends and Forecast to 2027

Source

Recent Posts

Alopecia Treatment Market

Global Alopecia Drugs Market Report

Global Alopecia Drugs Market Report

The Alopecia Drugs market is expected to grow from USD X.X million in 2020 to USD X.X million by 2026, at a CAGR of X.X% during the forecast period. The global Alopecia Drugs market report is a comprehensive research that focuses on the overall consumption structure, development trends, sales models and sales of top countries in the global Alopecia Drugs market.

The report focuses on well-known providers in the global Alopecia Drugs industry, market segments, competition, and the macro environment.

Under COVID-19 Outbreak, how the Alopecia Drugs Industry will develop is also analyzed in detail in Chapter 1.7 of the report.

In Chapter 2.4, we analyzed industry trends in the context of COVID-19.

In Chapter 3.5, we analyzed the impact of COVID-19 on the product industry chain based on the upstream and downstream markets.

In Chapters 6 to 10 of the report, we analyze the impact of COVID-19 on various regions and major countries.

In chapter 13.5, the impact of COVID-19 on the future development of the industry is pointed out.

A holistic study of the market is made by considering a variety of factors, from demographics conditions and business cycles in a particular country to market-specific microeconomic impacts. The study found the shift in market paradigms in terms of regional competitive advantage and the competitive landscape of major players.

Key players in the global Alopecia Drugs market covered in Chapter 4

Dr. Reddy’s Laboratories Ltd
Cipla Inc.
Aqua Pharmaceuticals
Bayer HealthCare
Merck
Helix BioMedix
The Himalaya Drug Company
GlaxoSmithKline
Johnson & Johnson
AndroScience

In Chapter 11 and 13.3, on the basis of types, the Alopecia Drugs market from 2015 to 2026 is primarily split into:_x000D_

Oral
Topical
Injectable

In Chapter 12 and 13.4, on the basis of applications, the Alopecia Drugs market from 2015 to 2026 covers:

Men
Women

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2026) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:

North America (Covered in Chapter 6 and 13)
United States
Canada
Mexico
Europe (Covered in Chapter 7 and 13)
Germany
UK
France
Italy
Spain
Russia
Others
Asia-Pacific (Covered in Chapter 8 and 13)
China
Japan
South Korea
South America (Covered in Chapter 10 and 13)
Brazil
Argentina
Columbia
Chile
Others

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2026

Global Alopecia Drugs Market Report

Source

Recent Posts

Hair Growth Cap ZeroT

Hair Growth Cap ZeroT

Hair Growth Cap ZeroT Is On Its Way to Raise Six Figures on Indiegogo

ZeroT Cap is ZEROi LAB’s third crowdfunding hat product and is their most innovative yet. It is a Low-level Light Therapy (LLLT) cap that makes professional hair treatment accessible to the average consumer. It has received a warm welcome from the global crowdfunding community for being a one-of-a-kind product offered at an affordable price. This is also ZEROi LAB’s third crowdfunding project

After reaching its Indiegogo funding goal in just 12 hours, the product went on to be featured as a Team Favorite by Indiegogo’s team as well as featured by many backer-community platforms like Kickbooster and BackerLand. With the campaign nearing $50,000 at its halfway point, it’s well on pace to reach six figures by the end.

ZeroT has three 20-minute modes of care—red light, blue light, and dual mode. The red light (650nm) reaches deep into the scalp to stimulate nutrient flow to the hair follicles while blue light (405nm) eliminates unnecessary oils and germs from the scalp’s surface. Dual mode allows total care with ten minutes of red light followed by ten minutes of blue light.

ZeroT also has three intensity levels, totalling at nine treatment options.

Despite the cap being wireless and flexible, making it more convenient to wear on the go, it is listed at a fraction of the price of other hair growth helmets on the market. Most caps of similar hair treatment are priced at $1,000 while ZeroT Cap’s Early Bird reward price is $140.

“In order to see an actual difference in your hair, you need to uphold a regular care routine,” said ZEROi LAB CEO Taekyeong Oh. “The goal of ZeroT Cap is to present an affordable and convenient solution to hair care that can be easily added to your daily routine. That’s why we keep ZeroT very cost-effective.”

To learn more about or support ZeroT Cap, visit its Indiegogo page

Hair Growth Cap ZeroT Is On Its Way to Raise Six Figures on Indiegogo

Source

Recent Posts